Sale!

Solid Tumor Combo1 EGFRALK1ROS1METPDL1 Test

7,500 د.إ

-25%

The “Solid Tumor Combo1 EGFRALK1ROS1METPDL1 Test” is a comprehensive molecular diagnostic assay offered by DNA Labs UAE, designed to identify genetic mutations and alterations in solid tumors. This advanced test focuses on a panel of genes including EGFR, ALK, ROS1, MET, and PD-L1, which are critical for the diagnosis, prognosis, and treatment planning for various cancers. By detecting mutations in these genes, the test can guide oncologists in choosing targeted therapies, thus personalizing the treatment approach for patients with solid tumors.

The cost of the Solid Tumor Combo1 Test is set at 7500 AED, reflecting the intricate technology and expertise involved in conducting this sophisticated analysis. Conducted in the state-of-the-art facilities of DNA Labs UAE, this test represents a significant advancement in cancer care, offering hope for more effective and tailored treatments for patients facing solid tumors.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Solid Tumor Combo1 EGFRALK1ROS1METPDL1 Test

Test Name: Solid Tumor Combo1 EGFRALK1ROS1METPDL1 Test

Components: Paraffin embedded tissue blocks

Price: 7500.0 AED

Sample Condition: Tumor tissue

Report Delivery: 5-7 days

Method: FISH, Sanger Sequencing, IHC

Test Type: Genetics

Doctor: Oncology

Test Department: Pre Test Information

Solid Tumor Combo1 EGFRALK1ROS1METPDL1 Test can be done with a doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

This combination of solid tumor targets includes EGFR, ALK1, ROS1, MET, and PDL1.

EGFR: Epidermal Growth Factor Receptor. Mutations in the EGFR gene are associated with certain types of cancer, including lung cancer. Targeting EGFR with drugs such as gefitinib or erlotinib can help slow or stop the growth of cancer cells.

ALK1: Anaplastic Lymphoma Kinase. ALK1 is a gene that can become fused with other genes in some types of cancer, such as non-small cell lung cancer. Targeting ALK1 with drugs such as crizotinib or alectinib can help shrink tumors in patients with ALK-positive cancer.

ROS1: C-Ros Oncogene 1. ROS1 is another gene that can become fused with other genes in some types of cancer, including non-small cell lung cancer. Targeting ROS1 with drugs such as crizotinib or entrectinib can help shrink tumors in patients with ROS1-positive cancer.

MET: Hepatocyte Growth Factor Receptor. Overexpression of MET has been associated with poor prognosis in several types of cancer, including lung cancer. Targeting MET with drugs such as crizotinib or cabozantinib can help slow or stop the growth of cancer cells.

PDL1: Programmed Death-Ligand 1. PDL1 is a protein that is expressed on the surface of some cancer cells and can interact with immune cells to suppress the immune response. Targeting PDL1 with drugs such as pembrolizumab or nivolumab can help activate the immune system to attack cancer cells.

Overall, targeting multiple pathways in solid tumors with a combination of drugs can improve treatment efficacy and reduce the risk of drug resistance.

Test Name Solid tumor Combo1 EGFRALK1ROS1METPDL1 Test
Components Paraffin embedded tissue blocks
Price 7500.0 AED
Sample Condition Tumor tissue
Report Delivery 5-7 days
Method FISH,Sanger Sequencing,IHC
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information Solid tumor Combo1 EGFR,ALK1,ROS1,MET,PDL1] can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

This combination of solid tumor targets includes EGFR, ALK1, ROS1, MET, and PDL1.

EGFR (epidermal growth factor receptor) is a protein that plays a role in cell growth and division. Mutations in the EGFR gene are associated with certain types of cancer, including lung cancer. Targeting EGFR with drugs such as gefitinib or erlotinib can help slow or stop the growth of cancer cells.

ALK1 (anaplastic lymphoma kinase) is a gene that can become fused with other genes in some types of cancer, such as non-small cell lung cancer. Targeting ALK1 with drugs such as crizotinib or alectinib can help shrink tumors in patients with ALK-positive cancer.

ROS1 (c-ros oncogene 1) is another gene that can become fused with other genes in some types of cancer, including non-small cell lung cancer. Targeting ROS1 with drugs such as crizotinib or entrectinib can help shrink tumors in patients with ROS1-positive cancer.

MET (hepatocyte growth factor receptor) is a protein that plays a role in cell growth and survival. Overexpression of MET has been associated with poor prognosis in several types of cancer, including lung cancer. Targeting MET with drugs such as crizotinib or cabozantinib can help slow or stop the growth of cancer cells.

PDL1 (programmed death-ligand 1) is a protein that is expressed on the surface of some cancer cells and can interact with immune cells to suppress the immune response. Targeting PDL1 with drugs such as pembrolizumab or nivolumab can help activate the immune system to attack cancer cells.

Overall, targeting multiple pathways in solid tumors with a combination of drugs can improve treatment efficacy and reduce the risk of drug resistance.